Barclays PLC Immatics N.V. Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
A detailed history of Barclays PLC transactions in Immatics N.V. stock. As of the latest transaction made, Barclays PLC holds 1,434 shares of IMTX stock, worth $16,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,434
Previous 1,560
8.08%
Holding current value
$16,820
Previous $16,000
6.25%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IMTX
# of Institutions
99Shares Held
76.6MCall Options Held
571KPut Options Held
210K-
Rtw Investments, LP New York, NY10MShares$117 Million1.94% of portfolio
-
Wellington Management Group LLP Boston, MA9.54MShares$112 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$94.9 Million2.72% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.43MShares$87.2 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$75.6 Million1.0% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $894M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...